JFG
MLTX icon

Jefferies Financial Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jefferies Financial Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,800
Closed -$442K – 1706
2024
Q1 		$442K Sell
8,800
-8,600
-49% -$467K ﹤0.01% 1099
2023
Q4 		$1.05M Buy
+17,400
New +$897K 0.01% 928

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jefferies Financial Group's MLTX Position: Q2 2026 in Review

Jefferies Financial Group sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2026, closing a stake of 500,000 shares — an estimated $9.32M sold.

Jefferies Financial Group first reported a position in MLTX in Q4 2022 and held it in 11 quarters. The position peaked at $9.32M in Q1 2026. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Jefferies Financial Group reported no remaining MoonLake Immunotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 500,000 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $9.32M.
  • Jefferies Financial Group first reported a position in MoonLake Immunotherapeutics in Q4 2022 and held it in 11 quarters.
  • Jefferies Financial Group's MoonLake Immunotherapeutics position peaked at $9.32M in Q1 2026.
  • 172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.